Evidence map›Paper›PMID 32631687›Full record

ReviewJournal francais d'ophtalmologie2020

[SARS-CoV-2, COVID-19 and the eye: An update on published data].

A Rousseau, J-R Fenolland, M Labetoulle

Abstract readReview
In one paragraph

Review in Journal francais d'ophtalmologie, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

A RousseauService d'ophtalmologie, CHU Bicêtre, hôpital Bicêtre, Assistance publique-Hôpitaux de Paris, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, Le Kremlin-Bicêtre, France; Département immunologie des maladies virales, auto-immunes, bactériennes et hématologiques. UMR 1184, CEA, Fontenay-Aux-Roses, France. Electronic address: antoine.rousseau@aphp.fr.
J-R FenollandService d'ophtalmologie, hôpital d'instruction des Armées Bégin, Saint-Mandé, France.
M LabetoulleService d'ophtalmologie, CHU Bicêtre, hôpital Bicêtre, Assistance publique-Hôpitaux de Paris, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, Le Kremlin-Bicêtre, France; Département immunologie des maladies virales, auto-immunes, bactériennes et hématologiques. UMR 1184, CEA, Fontenay-Aux-Roses, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has dramatically changed our daily lives as ophthalmologists. This general review firstly provides a better understanding of the virus responsible for the pandemic: the SARS-CoV-2, and the clinical manifestations of the COVID-19 disease. The second part is detailing the pathophysiology, clinical signs and challenges of ocular involvement, which seems rare and not functionally severe, but which may be a potential source of contamination. Finally, we discuss the preventive measures that need to be implemented in our daily practice to avoid any viral dissemination.

Indexed as

BetacoronavirusCoronavirus InfectionsCOVID-19Diagnostic Techniques, OphthalmologicalEyeEye Infections, ViralGenome, ViralHumansMicroscopy, ElectronPandemicsPneumonia, ViralSARS-CoV-2Virus IntegrationConjonctiviteConjunctivitisCOVID-19LarmesOcular surfaceSARS-CoV-2Surface oculaireTearsTransmission

Identifiers

PMID32631687
PMCPMC7260525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.